Securities Act of 1933

ECARX Secures $65 Million Convertible Note Financing Prior to its Planned Business Combination with COVA Acquisition Corp.

Retrieved on: 
Monday, November 14, 2022

LONDON, Nov. 14, 2022 /PRNewswire/ -- ECARX Holdings, Inc. ("ECARX" or the "Company"), a global mobility tech company, today announced that the Company has entered into an agreement with SPDB International (Hong Kong) Limited and CNCB (Hong Kong) Investment Limited for $65 million of convertible senior notes due 2025. The $65 million convertible note financing adds to the Company's $45 million in capital raised from strategic partners, Geely Holding Group and Luminar, and convertible note holder Lotus Technology, which was announced concurrently with the merger agreement entered into on May 26, 2022 between ECARX and COVA Acquisition Corp. ("COVA") related to the proposed business combination between ECARX and COVA.

Key Points: 
  • The $65 million convertible note financing adds to the Company's $45 million in capital raised from strategic partners, Geely Holding Group and Luminar, and convertible note holder Lotus Technology, which was announced concurrently with the merger agreement entered into on May 26, 2022 between ECARX and COVA Acquisition Corp.("COVA") related to the proposed business combination between ECARX and COVA.
  • China International Capital Corporation Hong Kong Securities Limited served as the financial advisor to ECARX leading the $65 million private convertible senior note financing.
  • COVA Acquisition Corp. is a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
  • The forward-looking statements in this communication represent the views of COVA and ECARX as of the date of this communication.

OpenText Announces Senior Secured Notes Offering as part of Micro Focus Acquisition Financing

Retrieved on: 
Monday, November 14, 2022

The Notes and related guarantees will be secured on the same basis as the Company's senior credit facilities.

Key Points: 
  • The Notes and related guarantees will be secured on the same basis as the Company's senior credit facilities.
  • The proposed offering is expected to be consummated prior to the consummation of the previously announced acquisition (the "Acquisition") of Micro Focus International plc.
  • The precise timing, size and terms of the offering (including the size and tenor of the Notes) are subject to market conditions and other factors.
  • OpenText, The Information Company, enables organizations to gain insight through market leading information management solutions, powered by OpenText Cloud Editions.

Freightos Announces Record Transactions and Gross Booking Value for Third Quarter of 2022

Retrieved on: 
Monday, November 14, 2022

JERUSALEM, Nov. 14, 2022 /PRNewswire/ -- Freightos Limited, a leading global freight booking and payment platform, today released its results for the third quarter of 2022, including record gross booking value (GBV) and transactions, by posting an update on its website.

Key Points: 
  • JERUSALEM, Nov. 14, 2022 /PRNewswire/ -- Freightos Limited, a leading global freight booking and payment platform, today released its results for the third quarter of 2022, including record gross booking value (GBV) and transactions, by posting an update on its website.
  • Freightos operates a leading, vendor-neutral booking and payment platform for international freight.
  • In addition, forward-looking statements reflect Freightos' expectations, plans or forecasts of future events and views as of the date of this communication.
  • However, while Freightos may elect to update these forward-looking statements at some point in the future, Freightos specifically disclaims any obligation to do so.

Volition Announces Clinical Research Study with Oncovet

Retrieved on: 
Monday, November 14, 2022

HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Key Points: 
  • HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.
  • The non-interventional study is being led by Dr. Jrme Benoit, Oncovet's Clinical Director, and will evaluate circulating nucleosomes of dogs and cats with cancer using Volition's Nu.Q Vet Cancer Test.
  • Dr. Jrme Benoit, Clinical Director at Oncovet, said: "Volition's Nu.Q Vet Cancer Test has already been shown to detect systemic cancers in dogs such as lymphoma and hemangiosarcoma.
  • Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "We are delighted to collaborate with Dr. Benoit and his team on this research study.

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

Retrieved on: 
Monday, November 14, 2022

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc. (MRI), a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada.   The conversion results in two key outcomes: QBIO receives a 15% equity stake in the form of common shares in MRI at a current valuation of MRI at CAD$30 million, and a royalty payment of $20 million on realization of future net sales.

Key Points: 
  • This dependable cycle of investment and de-risking has added significant value to QBIO's investment.
  • MRI's drug development pipeline is positioned to be a multi-billion dollar blockbuster franchise for years to come.
  • Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers.
  • Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.

Arbe Announces Q3 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022

TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) ("Arbe"), a global leader in next-generation 4D Imaging Radar Solutions, today announced financial results for its third quarter ended September 30, 2022.

Key Points: 
  • TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) ("Arbe"), a global leader in next-generation 4D Imaging Radar Solutions, today announced financial results for its third quarter ended September 30, 2022.
  • Net loss in Q3 2022 was $9.9 million, compared to a net loss of $13.3 million in Q3 2021.
  • The net loss in Q3 2022 included financial income of $1.0 million compared to $5.0 million of financial expenses in Q3 2021.
  • Arbe will host a live video webinar on Monday, Nov. 14 at 8:30 a.m. Eastern Time to discuss the company's third quarter 2022 financial results.

Envestnet, Inc. to Offer $350 Million of Convertible Notes

Retrieved on: 
Monday, November 14, 2022

When issued, the Notes will be general unsecured obligations, subordinated in right of payment to the Company's obligations under its revolving credit facility.

Key Points: 
  • When issued, the Notes will be general unsecured obligations, subordinated in right of payment to the Company's obligations under its revolving credit facility.
  • The interest rate, initial conversion rate and other terms of the Notes are to be determined at the time of pricing of the offering.
  • Contemporaneously with the pricing of the Notes in the offering, the Company expects to enter into separate and individually negotiated transactions (the "concurrent note repurchases") with certain holders of the Company's outstanding convertible notes.
  • This announcement is neither an offer to sell nor a solicitation of an offer to buy the Notes (or the shares of the Company's common stock into which the Notes are convertible), nor will there be any offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Maxar-built Galaxy 31 and Galaxy 32 Satellites for Intelsat Performing Properly After Launch

Retrieved on: 
Saturday, November 12, 2022

Galaxy 31 and Galaxy 32 are the first of five satellites that Intelsat contracted Maxar to build for the C-band transition.

Key Points: 
  • Galaxy 31 and Galaxy 32 are the first of five satellites that Intelsat contracted Maxar to build for the C-band transition.
  • Shortly after launch earlier today, both satellites deployed their solar arrays and began receiving and sending signals.
  • Next, Galaxy 31 and Galaxy 32 will begin firing thrusters to commerce their journeys to final geostationary orbit.
  • Todays launch of Galaxy 31 and Galaxy 32 is another milestone in Maxar and Intelsats decades-long relationship, said Chris Johnson, Maxar Senior Vice President and General Manager of Space.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 12, 2022

Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).

Key Points: 
  • Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).
  • For more information on the Warner Bros. class action go to: https://bespc.com/cases/WBD
    Olo provides software to restaurants to assist with online ordering and food-delivery coordination.
  • For more information on the PayPal class action go to: https://bespc.com/cases/PYPL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Polished.com Inc. (POL) Equity Alert: Contact Robbins LLP for Information Regarding Your Rights Against Polished.com Inc. (POL) f/k/a 1847 Goedeker Inc. (GOED)

Retrieved on: 
Saturday, November 12, 2022

What Now: Similarly situated shareholders may be eligible to participate in the class action against Polished.

Key Points: 
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Polished.
  • Shareholders who want to be appointed lead plaintiff for the class must file their papers by December 30, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • During the class period, defendants failed to disclose the truth regarding its lack of internal control over financial reporting.